Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring
Aim: To compare in terms of glycemic variability two premixed insulins, Premixed Human Insulin 30/70 (PHI) and Biphasic Aspart 30 (BiAsp30), using Continuous Glucose Monitoring (CGM) and to estimate the correlation of Glycated Albumin (GA) and Fructosamine (FA) with CGM data. Patients-Data: A total...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/9/1982 |
| _version_ | 1797535241367191552 |
|---|---|
| author | Charalampos Margaritidis Eleni Karlafti Evangelia Kotzakioulafi Konstantinos Kantartzis Konstantinos Tziomalos Georgia Kaiafa Christos Savopoulos Triantafyllos Didangelos |
| author_facet | Charalampos Margaritidis Eleni Karlafti Evangelia Kotzakioulafi Konstantinos Kantartzis Konstantinos Tziomalos Georgia Kaiafa Christos Savopoulos Triantafyllos Didangelos |
| author_sort | Charalampos Margaritidis |
| collection | DOAJ |
| description | Aim: To compare in terms of glycemic variability two premixed insulins, Premixed Human Insulin 30/70 (PHI) and Biphasic Aspart 30 (BiAsp30), using Continuous Glucose Monitoring (CGM) and to estimate the correlation of Glycated Albumin (GA) and Fructosamine (FA) with CGM data. Patients-Data: A total of 36 well-controlled patients with type 2 Diabetes Mellitus (T2DM) underwent 7-day CGM with PHI and subsequently with BiAsp30. GA and FA were measured at the first and last day of each week of CGM. Results: BiAsp30 was associated with lower Average Blood Glucose (ABG) during the 23:00–03:00 period (PHI: 135.08 ± 28.94 mg/dL, BiAsp30: 117.75 ± 21.24 mg/dL, <i>p</i> < 0.001) and the 00:00–06:00 period (PHI: 120.42 ± 23.13 mg/dL, BiAsp30: 111.17 ± 14.74 mg/dL, <i>p</i> = 0.008), as well as with more time below range (<70 mg/dL) (TBR) during the 23:00–03:00 period in the week (PHI: 3.65 ± 5.93%, BiAsp30: 11.12 ± 16.07%, <i>p</i> = 0.005). PHI was associated with lower ABG before breakfast (PHI: 111.75 ± 23.9 mg/dL, BiAsp30: 128.25 ± 35.9 mg/dL, <i>p</i> = 0.013). There were no differences between the two groups in ABG, Time In Range and Time Below Range during the entire 24-h period for 7 days, <i>p</i> = 0.502, <i>p</i> = 0.534, and <i>p</i> = 0.258 respectively, and in TBR for the 00:00–06:00 period <i>p</i> = 0.253. Total daily insulin requirements were higher for BiAsp30 (PHI: 47.92 ± 12.18 IU, BiAsp30: 49.58 ± 14.12 IU, <i>p</i> = 0.001). GA and FA correlated significantly with ABG (GA: r = 0.512, <i>p</i> = 0.011, FA: r = 0.555, <i>p</i> = 0.005). Conclusions: In well-controlled patients with T2DM, BiAsp30 is an equally effective alternative to PHI. |
| first_indexed | 2024-03-10T11:41:44Z |
| format | Article |
| id | doaj.art-bf3c63c4a8b249f9a0c724376f11205a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T11:41:44Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-bf3c63c4a8b249f9a0c724376f11205a2023-11-21T18:26:30ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-01109198210.3390/jcm10091982Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose MonitoringCharalampos Margaritidis0Eleni Karlafti1Evangelia Kotzakioulafi2Konstantinos Kantartzis3Konstantinos Tziomalos4Georgia Kaiafa5Christos Savopoulos6Triantafyllos Didangelos7Diabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDepartment of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, 72076 Tübingen, GermanyDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceDiabetes Center, 1st Propaedeutic Department of Internal Medicine, Medical School, “AHEPA” Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, GreeceAim: To compare in terms of glycemic variability two premixed insulins, Premixed Human Insulin 30/70 (PHI) and Biphasic Aspart 30 (BiAsp30), using Continuous Glucose Monitoring (CGM) and to estimate the correlation of Glycated Albumin (GA) and Fructosamine (FA) with CGM data. Patients-Data: A total of 36 well-controlled patients with type 2 Diabetes Mellitus (T2DM) underwent 7-day CGM with PHI and subsequently with BiAsp30. GA and FA were measured at the first and last day of each week of CGM. Results: BiAsp30 was associated with lower Average Blood Glucose (ABG) during the 23:00–03:00 period (PHI: 135.08 ± 28.94 mg/dL, BiAsp30: 117.75 ± 21.24 mg/dL, <i>p</i> < 0.001) and the 00:00–06:00 period (PHI: 120.42 ± 23.13 mg/dL, BiAsp30: 111.17 ± 14.74 mg/dL, <i>p</i> = 0.008), as well as with more time below range (<70 mg/dL) (TBR) during the 23:00–03:00 period in the week (PHI: 3.65 ± 5.93%, BiAsp30: 11.12 ± 16.07%, <i>p</i> = 0.005). PHI was associated with lower ABG before breakfast (PHI: 111.75 ± 23.9 mg/dL, BiAsp30: 128.25 ± 35.9 mg/dL, <i>p</i> = 0.013). There were no differences between the two groups in ABG, Time In Range and Time Below Range during the entire 24-h period for 7 days, <i>p</i> = 0.502, <i>p</i> = 0.534, and <i>p</i> = 0.258 respectively, and in TBR for the 00:00–06:00 period <i>p</i> = 0.253. Total daily insulin requirements were higher for BiAsp30 (PHI: 47.92 ± 12.18 IU, BiAsp30: 49.58 ± 14.12 IU, <i>p</i> = 0.001). GA and FA correlated significantly with ABG (GA: r = 0.512, <i>p</i> = 0.011, FA: r = 0.555, <i>p</i> = 0.005). Conclusions: In well-controlled patients with T2DM, BiAsp30 is an equally effective alternative to PHI.https://www.mdpi.com/2077-0383/10/9/1982diabetes mellitus 2continuous glucose monitoringpremixed human insulinpremixed insulin analogglycated albuminfructosamine |
| spellingShingle | Charalampos Margaritidis Eleni Karlafti Evangelia Kotzakioulafi Konstantinos Kantartzis Konstantinos Tziomalos Georgia Kaiafa Christos Savopoulos Triantafyllos Didangelos Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring Journal of Clinical Medicine diabetes mellitus 2 continuous glucose monitoring premixed human insulin premixed insulin analog glycated albumin fructosamine |
| title | Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring |
| title_full | Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring |
| title_fullStr | Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring |
| title_full_unstemmed | Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring |
| title_short | Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring |
| title_sort | comparison of premixed human insulin 30 70 to biphasic aspart 30 in well controlled patients with type 2 diabetes using continuous glucose monitoring |
| topic | diabetes mellitus 2 continuous glucose monitoring premixed human insulin premixed insulin analog glycated albumin fructosamine |
| url | https://www.mdpi.com/2077-0383/10/9/1982 |
| work_keys_str_mv | AT charalamposmargaritidis comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT elenikarlafti comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT evangeliakotzakioulafi comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT konstantinoskantartzis comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT konstantinostziomalos comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT georgiakaiafa comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT christossavopoulos comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring AT triantafyllosdidangelos comparisonofpremixedhumaninsulin3070tobiphasicaspart30inwellcontrolledpatientswithtype2diabetesusingcontinuousglucosemonitoring |